KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Equity (2016 - 2025)

Historic Return on Equity for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q3 2025 value amounting to 1.14%.

  • Rigel Pharmaceuticals' Return on Equity rose 13100.0% to 1.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.14%, marking a year-over-year increase of 13100.0%. This contributed to the annual value of 1.38% for FY2024, which is 25700.0% down from last year.
  • Rigel Pharmaceuticals' Return on Equity amounted to 1.14% in Q3 2025, which was up 13100.0% from 1.95% recorded in Q2 2025.
  • Rigel Pharmaceuticals' Return on Equity's 5-year high stood at 7.02% during Q3 2022, with a 5-year trough of 54.15% in Q2 2022.
  • For the 5-year period, Rigel Pharmaceuticals' Return on Equity averaged around 2.07%, with its median value being 0.66% (2024).
  • Per our database at Business Quant, Rigel Pharmaceuticals' Return on Equity plummeted by -540400bps in 2022 and then soared by 555900bps in 2023.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Return on Equity stood at 0.45% in 2021, then soared by 884bps to 3.5% in 2022, then tumbled by -76bps to 0.83% in 2023, then plummeted by -471bps to 3.08% in 2024, then soared by 137bps to 1.14% in 2025.
  • Its Return on Equity stands at 1.14% for Q3 2025, versus 1.95% for Q2 2025 and 3.4% for Q1 2025.